curesearch.org

MAY 6 - 7, 2018

1

ERIC AGUIAR, M.D.Partner, Aisling CapitalDr. Aguiar joined Aisling in 2016. Prior to joining Aisling, Dr. Aguiar was a partner at Thomas, McNerney and Partners, a $600 million health care focused venture capital and growth equity fund, from 2007-2015. Dr. Aguiar was a Managing Director of HealthCare Ventures, a health care venture capital fund, from 2001-2007. He currently sits on the boards of Biohaven

and Invitae Corporation. His prior board seats have included Amarin, Oriel Therapeutics, Inc. (acquired by Novartis AG), Virdante Pharmaceuticals, Inc. (acquired by Momenta Pharmaceuticals), CardioKine, Inc. (acquired by Cornerstone Therapeutics), SkinMedica, Inc. (acquired by Allergan), Vaxinate, Inc., Metaphore, and 3-D Pharmaceuticals (acquired by Johnson & Johnson). He was CEO of Genovo, Inc. (acquired by Targeted Genetics), a biopharmaceutical company that specialized in gene delivery and gene regulation. He was also executive director of TheraTech, Inc. (acquired by Watson Pharmaceuticals). He was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997. Dr. Aguiar is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations. He received his Medical Degree with honors from Harvard Medical School. He graduated with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst.

SCOTT A. ARMSTRONG, M.D., PH.DChair, Pediatric Oncology, Dana-Farber Cancer InstituteDr. Scott A. Armstrong is Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute, and the David G. Nathan Professor of Pediatrics at Harvard Medical School. Dr. Armstrong received his M.D. and Ph.D from the University of Texas Southwestern Medical School in Dallas, Texas. Dr. Armstrong’s studies have led to several findings that point to

promising new therapies. The major focus of his career has been on delineating the biology of childhood cancers and the development of new therapeutic approaches for children with cancer. He has developed a large research program that has focused on the mechanisms of leukemia development and the relationship between leukemia and normal hematopoietic stem cells. His lab has made fundamental contributions to the understanding of how leukemia arises from different cells in the hematopoietic system. Through this work, he has shown that myeloid leukemia stem cells are often most similar to committed myeloid progenitors that inappropriately express stem cell programs; a concept that has now been replicated in multiple cancers. He has also developed an interest in the mechanisms by which chromatin modifications control leukemogenic gene expression and has used this understanding to develop small molecule approaches that he continues to pursue. This work has led to the development of clinical trials that are being assessed in adults and children with cancer.

Attendee Biographies

2

ELLY BARRY, M.D., M.M.SC.Senior Medical Director, Global Clinical Lead for Pediatric Oncology and Xtandi, Pfizer Global Product Development OncologyElly Barry, M.D., M.M.Sc. is a board-certified pediatrician and pediatric hematologist/oncologist, currently serving as the Global Clinical Lead for Pediatric Oncology at Pfizer, and responsible for developing and implementing strategy and deliverables related to pediatric development

plans. While at Pfizer, she has contributed to the development of PIPs/PPSRs across a number of compounds, including bosutinib, gemtuzumab ozogamicin, inotuzumab ozogamizin, and sunitinib. She is the Head of the Pediatric Oncology Leadership Team at Pfizer, and a member of Pfizer’s Pediatric Council. She is also the Global Clinical Lead for the clinical development of enzalutamide, with a focus on prostate cancer.

Elly received her MD degree from Yale University School of Medicine in New Haven, before completing residency training in pediatrics at Tufts-New England Medical Center/Floating Hospital for Children in Boston, and fellowship training in pediatric hematology/oncology at Boston Children’s Hospital/Dana-Farber Cancer Institute in Boston. She remained on staff at DFCI as an Instructor in Pediatric Hematology/Oncology and Bone Marrow Transplantation, while obtaining a Masters in Medical Science degree from Harvard Medical School. Her previous industry roles at Genzyme and Millennium have focused on the early and late development of drugs for hematologic malignancies, breast, and renal cancers.

MELANIE SCHNOLL BEGUN, J.D.Managing Director of Philanthropy Management and Co-Director Global Sports & Entertainment, Morgan Stanley Melanie Schnoll Begun leads Morgan Stanley’s Philanthropy Management and exemplifies her professional work by living a life of committed action. For over 18 years, she has worked with many of the firm’s wealthiest and most influential clients. She develops focus areas for client’s philanthropy;

engages senior and millennial generations in their foundation’s governance; designs customized grant portfolios; aligns client values with impactful investing; and facilitates giving circles, board retreats and educational events.

In 2000, Melanie launched Morgan Stanley GIFT, the firm’s global Donor-Advised Fund. In 2012, she launched Foundation Management Services, a philanthropic advisory and administrative services platform for corporate and private foundations. She is also responsible for the firm’s Nonprofit and Endowment Consulting Services. She received her law degree from Quinnipiac University Law School.

JONATHON BEHR, PH.D. Managing Director, JDRFAs the founding Managing Director of the T1D Fund, Jon has driven the creation of the fund’s strategy, operating model, and team, while leading deals and driving portfolio construction across all fund priority areas and technology types.  

Jon has spent his career identifying promising cutting edge innovation, and then bridging the gap to commercial translation. After various research experiences, Jon held senior venture creation roles, including Principal at PureTech Ventures (PRTC) and Vice President of New Ventures for Enlight Biosciences. Prior to the T1D Fund, Jon was a Market Sector Leader and Executive in Residence at Partners Healthcare Innovation, where he was responsible for driving technology translation from research hospitals affiliated with Harvard Medical School. In those roles Jon co-founded and supported seven companies (including Vedanta Biosciences at PureTech, Entrega at Enlight, and Tilos Therapeutics at Partners) and took senior operating roles in several. Jon also has extensive experience supporting and managing portfolio companies in the board room including six voting or observer positions.

Jon has a doctorate in Biological Engineering from Massachusetts Institute of Technology as a Howard Hughes Medical Institute fellow, and received his Bachelor of Science summa cum laude as phi-beta-kappa co-valedictorian from Rice University.

3

4

RANJIT BINDRA, M.D. PH.D.Departments of Therapeutic Radiology and Experimental Pathology, Yale School of MedicineDr. Ranjit Bindra is a physician-scientist and biotech entrepreneur at the Yale School of Medicine. Clinically, he treats adult and pediatric primary CNS tumors. In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that

IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and it has received international attention with major clinical implications. Building on this discovery, a more recent study in his laboratory was just accepted for publication in Nature

Genetics, which highlights the expanding significance of this work: specific tumor-associated mutations induce the aberrant production of citric acid cycle-related metabolites, which drives genetic instability and BRCAness. Dr. Bindra is now translating this work directly into patients, in four phase I/II clinical trials, including an innovative, biomarker-driven trial specifically targeting the Adolescent/Young Adult (AYA) cancer patient population. In addition, he is lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in adult IDH1/2-mutant solid tumors (NCT03212274).

As a biotech entrepreneur, Dr. Bindra has started several life sciences ventures over the last 10 years. Most recently, he co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Cybrexa is led by an experienced business team that has built numerous successful biotech ventures and raised hundreds of millions of dollars in venture capital.

Dr. Bindra is also very active on social media (@ranjitbindra) as both a patient and science advocate, with an interest in garnering support for cancer research, and in educating the community about the latest treatment options that are available. To this end, he has twice appeared on the Yale Cancer Center Answers show on NPR. He was also voted to represent the Yale School of Medicine for the InspireYale 2016, a one-day event that showcases the work of various inspirational thought leaders from the 13 graduate and professional schools at Yale.

Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center in 2012.

BRUCE BLOOM, DDS, J.D. President and Chief Science Officer, Cures Within ReachBruce Bloom, DDS, J.D. is Chief Executive Officer of Cures Within Reach, a non-profit saving lives by repurposing human approved drugs, devices, diagnostics and nutraceuticals to quickly deliver safe and affordable treatments and cures for diseases that have no currently effective therapy.

Cures Within Reach uses CureAccelerator™, the only global online repurposing research collaboration platform, to bring together clinicians, researchers, funders, and industry to create and conduct pilot clinical trials that drive more treatments to more patients more quickly.

Dr. Bloom became an Ashoka Social Entrepreneur Fellow for his system-changing solutions to finding new treatments for unsolved diseases. He is the Patient Advisory Board Chair for the Institute for Translational Medicine, Board member of the Drug Discovery Center at the University of Illinois, the Director of Scientific Affairs for Vision for Tomorrow, on the Science Advisory Boards of Rediscovery Life Sciences, the GARROD AKU Consortium, the Dr. Ralph and Marian Falk Medical Research Trust Awards Programs, the Findacure Fundamental Disease Charity, and Healx, LTD, is the Chair of the Governance Committee of the Kendall College Charitable Trust, is a member of the Board of Councilors of Midwestern University, and a member of the editorial board of ASSAY and Drug Development Technologies.

SAMUEL C. BLACKMAN, M.D., PH.D. Senior Vice President, Head of Clinical Development, Silverback Therapeutics, Inc.Sam Blackman is a physician-scientist trained in pediatric hematology-oncology and pediatric neuro-oncology. For the past 10 years he has been focused on the early clinical development of novel cancer therapeutics

and has held various positions of increasing responsibility within the pharmaceutical and biotechnology industry. In his present role at Silverback Therapeutics he is responsible for end-to-end clinical development of new protein-based immunotherapeutics for cancer. Prior to this role he was Senior Medical Director at Juno Therapeutics where he was responsible for clinical development of novel cellular immunotherapeutics for leukemia, including chimeric antigen receptor (CAR) T cell therapies and high-affinity T cell receptor (TCR) therapies. He was responsible for the pediatric development strategy for dabrafenib and trametinib while at GlaxoSmithKline, which represent one of the earliest industry-sponsored “basket trials” for pediatric cancer.

Dr. Blackman is a graduate of the pediatric hematology/oncology fellowship program at the Dana-Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Cincinnati Children’s Hospital Medical Center. He received his M.D. and Ph.D. degrees at the University of Illinois at Chicago College of Medicine and Department of Pharmacology, and his undergraduate degree in philosophy from the University of Chicago.

5

6

JAMES (JAY) BRADNER, M.D.President, NovartisJames (Jay) Bradner, M.D., has been President of the Novartis Institutes for BioMedical Research (NIBR) since March 2016. He is a member of the Executive Committee of Novartis.

From 2005 through 2015, Dr. Bradner served on the research faculty of Harvard Medical School and as an attending physician in stem cell transplantation within the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States. He has co-founded five biotechnology companies and has co-authored more than 200 scientific publications and 30 US patent applications.

Dr. Bradner is a graduate of Harvard College and the University of Chicago Medical School in the US. He completed his residency in medicine at Brigham and Women’s Hospital, his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute, and his postdoctoral training in chemistry and chemical biology at Harvard University. He has received many honorific awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.

ELLEN BOLOTIN, M.D., PH.D.Vice President, Pediatric Development, Bayer HealthCare PharmaceuticalsEllen Bolotin is the Vice President of Pediatric Development at Bayer, responsible for overseeing pediatric global development, including small molecules, monoclonal antibodies, ADC, and radiotherapy. Her expertise is in pediatric program development from indication selection, PIP to study

protocol development, networking with pediatric oncology networks, KOLs and cooperative groups. It includes early assessment and prioritization of compounds in non-competitive environment internal and external; harmonization of regulatory submissions to FDA and EMA; Innovative clinical and statistical study design, long term follow up, education and training.

Dr. Bolotin received her M.D. degree from St Petersburg Pediatric Medical School and Ph.D. from Institute of Hematology and transfusion medicine training in pediatric hematology/oncology at University of Southern California and has held academic positions at USC and City of Hope in Pediatric Hematology/Oncology and bone marrow transplantation. Prior to Bayer, she served as Senior Director, Head of Experimental Medicine at Daichi Sankyo.

7

VICKIE BUENGER President, Coalition Against Childhood Cancer (CAC2)

Vickie Buenger serves as clinical professor at the Mays Business School and the Professional Program for Biotechnology at Texas A&M University and as the president of the Coalition Against Childhood Cancer (CAC2).

Vickie’s daughter, Erin, fought neuroblastoma for seven years. Since her death, Vickie has devoted time and energy to launching CAC2 on behalf of the many dedicated organizations striving to make a difference for children with cancer. She combines her academic background with her interest in the science and policy of childhood cancer and has spoken before gatherings of scientists, clinicians, regulators, industry representatives, and advocates in the United States and Europe.

J. SCOTT CAMERON, M.D. PH.D. Senior Director and Clinical Program Leader, NovartisScott is an Executive Director, Oncology Research Physician in Translational Clinical Oncology at Novartis. Prior to joining Novartis in 2010, Scott was a pediatric hematologist-oncologist, laboratory scientist, teacher and program director in the Simmons Cancer Center at the University of Texas Southwestern Medical Center. He received a Ph.D. in Genetics from Cold

Spring Harbor Laboratory, and is a cum laude graduate of Harvard Medical School/MIT. He was a postdoctoral fellow with Dr. H. Robert Horvitz at the Massachusetts Institute of Technology, working on the genetic control of programmed cell death. At Novartis, he leads the clinical research program for the PD-1 inhibitor, PDR001.

HUBERT CARON, M.D, PH.D. Senior Medical Director, Hoffman-La Roche AGHubert Caron, M.D., Ph.D., Principal Medical Director of Pediatric Oncology at Roche, Basel and Research Professor at AMC, Amsterdam.

Dr. Caron is trained as a pediatric oncologist and worked in clinical practice and academic research until recently. He joined Roche in 2014 and became

the Global Development Team Lead within the iPODD pediatric oncology team, which is responsible for the pediatric clinical and regulatory development of the Roche Genentech oncology portfolio in the iMATRIX trial structure to bring new and life-saving therapies to children with cancer. He has implemented a preclinical pediatric screening platform in Roche to support rational Mechanism-of-Action based development of the Roche Genentech anticancer drugs in the “best matching” pediatric cancers. Furthermore, he is co-leading an IMI2 EU research consortium, consisting of a public-private partnership of 11 academic institutions, 3 SMEs and 5 pharmaceutical companies, to develop a large PDX preclinical testing platform for 10 high risk pediatric cancer types.

He holds a full professorship in pediatric oncology at the AMC, Amsterdam, Netherlands and is a principal investigator for several tumor-biology-driven preclinical translational research projects. He established a very active ‘late effect’ research group in his department. He was also actively involved in projects in evidence-based medicine and in quality of care.

8

CASON CARTERDirector and Head of Government Affairs, CitadelCason Carter is Director and Head of Government Affairs at Citadel, one of the most respected and successful investment firms in the world. In this role, he oversees public policy strategies for the firm and advises Citadel Founder and CEO Ken Griffin on legislative matters, political engagement efforts and philanthropic initiatives.

Prior to joining Citadel, Mr. Carter managed government and external affairs at Alliance Resource Partners, where he served as Vice President of Public Affairs and Corporate Counsel. Previously, he served as an Attorney at GableGotwals, where he specialized in complex business litigation, and simultaneously served as an elected City Counselor in Tulsa, Oklahoma.

Mr. Carter is an advocate for pediatric cancer research, serving on the Board of the Children’s Cancer Therapy Development Institute and as a Trustee for the Scott Carter Foundation for pediatric cancer research. He received his J.D. from Georgetown University Law Center and bachelor’s degree from Duke University.

PAULA CARTERCo-Founder, Scott Carter Foundation, Board Member, CureSearch for Children’s CancerIn 1992, Paula Carter and her husband, Mike co-founded the Scott Carter Foundation in memory of their youngest son. The foundation has since raised money for pediatric cancer research. Paula serves as executive director and handles communications and finance. She also participates in development. She is an advocate for children with cancer and does public

speaking sharing her personal journey as well as the history of the foundation. Paula serves on the Board of Directors for Curesearch.

Mrs. Carter recceived her Bachelor of Science in Education from Oklahoma State University in 1970. Prior to 1992, Mrs. Carter worked in education, teaching in both the public and private sectors. Her teaching experience includes music, speech & drama, mathematics, language arts, social studies, science and gifted & talented (grades K-6). Today, although retired, she continues to teach Bible studies to both adult women and to school age children - grades 1 - 4. Prior to her retirement, Mrs. Carter volunteered for organizations including Tulsa Opera, Tulsa Ballet, Children’s Day Nursery, Ronald McDonald House and the Junior League of Tulsa. She also co-founded and directed a children’s performance troupe and an independent business of party/ event planning.

Since retirement, Mrs. Carter continues to speak publicly on topics including The Bible, Faith, Grief, Pediatric Cancer Research and Life Skills such as parenting. She serves as an Area Director for the state of Oklahoma for Community Bible Study, an international ministry.

SONYA DASHealthcare Finance Research Assistant, MIT Sloan School of MedicineSonya Das is an undergraduate researcher at the MIT Laboratory for Financial Engineering. Research interests focus on analyzing various business and financing models to stimulate investment in neglected disease areas.

DAVY CHIODIN, PHARM.D.Vice President, Regulatory Science, Acerta Pharma (AstraZeneca Group) Davy Chiodin is Vice President, Regulatory Science & Quality Assurance at Acerta Pharma, AstraZeneca’s Hematology Center of Excellence, based in South San Francisco, CA. Before joining Acerta in 2016, he most recently served as the Senior Regulatory Program Director and Global Regulatory Leader for the Innovative Pediatric Drug Development group at Genentech/

Roche (iPODD) working with EMA and FDA at developing innovative pediatric regulatory strategies. Davy brings in global Regulatory expertise in all stages of drug development and commercialization, across tumor types, in solid and hematologic malignancies, most recently including the U.S. FDA approval of Calquence (acalabrutinib) for patients with previously treated Mantle Cell Lymphoma.

MATTHEW DE SILVACEO, Notable Labs Matt studied economics before joining Merrill Lynch. He then joined Peter Thiel’s hedge fund as a portfolio manager. 

In 2013 his dad was diagnosed with three brain tumors. He searched every clinical trial, but most excluded him for multiple tumors. Many remaining

trials repurposed approved drugs for brain cancer. Matt collaborated with the oncologist to prescribe those drugs in a personalized cocktail, but there were too many options with unknown safety and efficacy.

This led him to start Notable Labs in San Francisco, which uses robotics and AI to test thousands of drug combinations directly on blood cancer cells from a patient in 72 hours. The reports rank based on killing specificity of cancer cells vs. normal cells. Notable partners with pharmaceutical companies and hospitals, and raised $18m from Founder’s Fund, Builder’s, and Y Combinator.

9

10

ARINDAM DHAR, MD, PH.D. Clinical Development Lead, Cancer Epigenetics, GlaxoSmithKlineArindam received his M.B.B.S. degree from the University of Calcutta and his M.D. and Ph.D. degrees from the All India Institute of Medical Science in India. After completing his Residency in Internal Medicine, he served in the Hematology Clinic at the School of Tropical Medicine, Calcutta. Subsequently,

he conducted research on Retinoid biology for treatment of cancer in the Gynecologic Oncology Division at the University of Oklahoma HSC. He worked on Cancer Prevention at the National Cancer Institute and then as a Fellow in the Inter-agency Oncology Task Force (a NCI-FDA joint endeavor to facilitate cancer therapeutic development). Arindam joined Bristol-Myers Squibb in 2007 as Associate Medical Director of early phase oncology clinical studies and leading the development of the IGF-1R TKI program. In 2011, he transitioned to late phase Global Clinical Research as Medical Director in the anti-PD-1 (nivolumab) program, leading the first combination studies of nivolumab with TKIs and ipilimumab in Renal Cell Cancer. Arindam joined Glaxo-Smith Kline in 2013 to head the Cancer Epigenetics clinical development program.

SCOTT DIEDE, M.D., PH.D.Senior Clinical Director, Oncology Late Stage Development, Merck Scott Diede, M.D., Ph.D. is the Senior Clinical Director in Global Clinical Development on the pembrolizumab (KEYTRUDA) melanoma team at Merck. He is also the Clinical Director of a Phase I/II pediatric trial of pembrolizumab in childhood malignancies (NCT02332668), a Phase Ib/III Amgen-led study

of the combination of talimogene laherparepvec (T-Vec) with pembrolizumab in adults with advanced melanoma (NCT02263508), and a Phase III collaborative study with Incyte exploring the combination of the IDO1 inhibitor epacadostat with pembrolizumab in adults with advanced melanoma (NCT02752074). Before Joining Merck in 2014, he was an attending physician as a pediatric hematologist-oncologist at Seattle Children’s Hospital and conducted research at the Fred Hutchinson Cancer Research Center.

JASON FANGUSARO, M.D. Senior Head, Pediatric Nuero-Oncology, Ann & Robert H. Lurie Children’s Hospital of Chicago Jason Fangusaro, M.D. is the Director of the Brain Tumor Program at Lurie Children’s Hospital in Chicago and the Vice Chair of the Pediatric Brain Tumor Consortium (PBTC). He has an expertise and specialty training in treating children with central nervous system malignancies, including

brain and spinal cord tumors. His primary area of research interest is in the development of clinical trials and novel therapeutics in pediatric brain tumors in an effort to improve survival outcomes and minimize toxicities. He devotes much of his time to clinical trial research within the Children’s Oncology Group (COG), the Pediatric Brain Tumor Consortium (PBTC) and with industry.

RICARDO GARCIACEO & Co-Founder, Oncokids Biosciences, Inc. Ricardo Garcia is a natural-born entrepreneur. Passionate about taking on new challenges and with a background in computer engineering and management and business administration, he sold his first company at the age of 22. This led to the creation and development of various companies, predominantly in the field of technology with a strong bent towards innovation.

His son Richi’s brain tumour diagnosis in 2011 forced him to abandon all his plans and move to Boston to save his life. 

Ricardo discovered the obstacles that existed, as well as the lack of provision and support in this field through his own personal experience, and decided to create the Richi Childhood Cancer Foundation, a 501 (c) (3) non profit organization established in the US and with links around the world, and to launch Oncokids Biosciences, an unprecedented life science company focused on bringing innovation to children with cancer.

Ricardo also sits on the Pediatric Patient Advisory Committee at the Dana-Farber Cancer Institute in Boston.

11

12

LINDEE GOH, PH.D.Partner, Tapestry Networks Lindee Goh, Ph.D. is a partner with Tapestry Networks and leads the healthcare practice. She works with public and private sector leaders to develop effective strategies to improve clinical outcomes while fostering sustainable healthcare innovation. Throughout her career, Lindee has enjoyed the challenge of bridging scientific, clinical, and corporate worlds to

address cross-sector challenges.

Healthcare public-private working groups Lindee has co-led have included focuses on: initial design and implementation of the parallel scientific advice process, a new approach to regulation and reimbursement of medical products in Europe; collaborative recommendations to address innovation, diagnostics, and infrastructure challenges of Alzheimer’s disease; U.S.-focused pilot approach to molecular diagnostic quality assurance as relevant to precision medicine; and innovative approaches to healthcare financing.

Prior to Tapestry Networks, Lindee led teams at the Boston Consulting Group, working in biopharma, payer, and provider spaces, with expertise on strategy, organizational and operational transformation, and addressing issues in innovation, quality, and safety.

Lindee holds a doctorate in biology, working on basic cancer biology as a Howard Hughes Medical Institute Fellow at the Center for Cancer Research at Massachusetts Institute of Technology (MIT). She did post-graduate work at MIT as a Leukemia and Lymphoma Fellow working in neuroscience. She has published articles in leading scientific journals including Nature and Development. She holds a black belt in aikido and lives in Somerville, MA with her husband and two sons.

TESSA GATZDirector of Communications, CureSearch for Children’s Cancer Tessa Gatz is the Director of Communications of CureSearch for Children’s Cancer where she directs the organization’s extensive marketing and communications strategies. Tessa leads direct marketing and digital campaigns to convey the mission and help achieve CureSearch goals.

Tessa has more than 10 years of communications and marketing experience in non-profit environments. Along with non-profits, she has agency and media relations experience. Tessa was recently named an honoree for the USAE and Association Forum Forty Under 40 Award.

Tessa holds a bachelor’s degree from The Ohio State University and a Master’s in Communication Management from the University of Southern California. Residing in Chicago, Tessa is involved with a number of organizations such as the American Marketing Association, Association Forum, and the Ohio State Alumni Club where she serves as Vice President. Tessa is proud to work with a collaborative team to move forward the important work and mission of CureSearch.

13

NANCY GOODMAN, J.D. CEO, Kids v CancerNancy Goodman, JD is CEO of Kids v Cancer, a nonprofit that was lead advocate and author of two Federal laws to incentivize and require pharmaceutical companies to develop drugs for children. The Creating Hope Act pediatric priority review voucher program, passed into law in 2012 as 12 U.S.C. 360ff, established a market-based incentive, a voucher,

for companies to develop drugs expressly for children with pediatric rare diseases, including pediatric cancers. Over $1.2 billion in vouchers have been traded since the establishment of the program. The RACE for Children Act, which amends the Pediatric Research Equity Act (PREA), 21 U.S.C. 355c, was passed into law in 2017, authorizes the FDA to require companies developing cancer targeted therapies to undertake pediatric studies when the molecular targets of the drugs are substantially relevant to pediatric cancers.

Kids v Cancer was selected by Fast Company Magazine as top ten most innovative non-profits in 2016 and won the Peter Drucker Nonprofit Innovation Award in 2015. Nancy was awarded the Rare Disease Legislative Advocates Rare Disease Award and The One Hundred: top cancer leaders by Massachusetts General Hospital. She serves on the National Cancer Institute Board of Scientific Counselors.

Nancy’s son, Jacob, died of a pediatric brain cancer when he was ten. Nancy is a graduate of the University of Chicago Law School, Harvard Kennedy School of Government and University of Pennsylvania.

LIA GORE, M.D. Professor of Pediatrics, Hematology and Medical Oncology, Children’s Hospital ColoradoDr. Gore’s interests focus on the development of novel cancer therapeutics with a particular emphasis on pediatric and hematological malignancies. She has extensive experience in constructing, conducting, analyzing, and presenting phase I and II clinical trials in both adults and children,

focusing on biologically-rational, molecularly targeted agents and combination regimens. She has served as the Principal Investigator or co-Principal Investigator on more than 200 national and international clinical trials. Dr. Gore serves on the Executive Committee for Acute Lymphoblastic Leukemia in the Children’s Oncology Group and is the co-Director of the Developmental Therapeutics Program in the University of Colorado’s NCI-designated Comprehensive Cancer Center. In 2014, she was named the inaugural Clark Chair in Pediatric Cancer Therapeutics at Children’s Colorado, and in 2015, the Section Chief for Pediatric Hematology/Oncology/Bone Marrow Transplant at Children’s Hospital Colorado, where she currently holds the Ergen Endowed Chair in Pediatric Oncology. Dr. Gore has worked on the Oncology Drug Advisory Committee (ODAC) to the U.S. FDA, the U.S. NCI’s Cancer Therapy Evaluation Program, the Developmental Therapeutics Study Section of the NCI/NIH, the European Medicines Agency, and the International BFM Committee for Childhood Leukemia.

14

KEVIN GRIMES, M.D.Director, Stanford SPARK Kevin Grimes is Professor of Chemical and Systems Biology and Co-director of the SPARK Program in Translational Research at Stanford University School of Medicine. He received his M.D. from Brown University and completed internal medicine training at Stanford before joining the Stanford Internal Medicine faculty. Grimes subsequently received his MBA at Stanford

and was selected as a White House Fellow serving as Special Assistant to the Secretary of Defense. He then spent fifteen years working in the medical device, life-science consulting, and biotechnology sectors prior to returning to Stanford to co-direct SPARK. Grimes teaches graduate student courses on drug discovery and continues to teach and practice internal medicine. He has received the David Rytand Award for Excellence in Clinical Teaching and the Faculty Award for Excellence in Graduate Teaching. 

SPARK’s mission is to advance promising research discoveries into the clinic as new therapeutics and diagnostics, and to educate faculty, post-doctoral fellows and students regarding the translational process. SPARK participants receive modest funding, education regarding translational research, and targeted mentorship on their specific projects. Over one hundred volunteers from the biotechnology sector serve as advisors. Approximately 60% of projects completing the program have been licensed and/or advanced to clinical trials.

ANNIE GOULD Childhood Cancer Advocate, Board of Director, CureSearch for Children’s Cancer Annie Gould is a Childhood Cancer Advocate. Her daughter, Eloise, passed away in May 2010 from rhabdomyosarcoma. Because of her death, she became very passionate in finding the right place to channel her energies and really make a difference in the lives of children with cancer.

Prior to Eloise’s treatment in March 2008, Annie had her own floral design business with many prominent clients in the Charlottesville area. She chose to not return to this after Eloise’s death. Annie’s passion is to be involved with seeking a cure for childhood cancer. She has been able to meet some truly remarkable people in this endeavor and hope to continue doing so.

Annie is honored to serve on CureSearch’s Board. Her involvement as a CureSearch walk volunteer in Wilmington, Delaware during the fall of 2010 led her to have a walk in Charlottesville. As of today, she has chaired 3 Walks (April 2011, April 2012 and September 2013) and raised a total of $200,000.

JONATHAN GRUBER, PH.D. Professor of Economics, Massachusetts Institute of TechnologyJonathan Gruber, Ph.D. is the Ford Professor of Economics at the Massachusetts Institute of Technology, where he has taught since 1992. He is also the Director of the Health Care Program at the National Bureau of Economic Research, and President of the American Society of Health Economists. He is a member of the Institute of Medicine, the

American Academy of Arts and Sciences, the National Academy of Social Insurance, and the Econometric Society. He has published more than 160 research articles, has edited six research volumes, and is the author of Public Finance and Public Policy, a leading undergraduate text, and Health Care Reform, a graphic novel. In 2006 he received the American Society of Health Economists Inaugural Medal for the best health economist in the nation aged 40 and under.

During the 1997-1998 academic year, Dr. Gruber was on leave as Deputy Assistant Secretary for Economic Policy at the Treasury Department. From 2003-2006 he was a key architect of Massachusetts’ ambitious health reform effort, and in 2006 became an inaugural member of the Health Connector Board, the main implementing body for that effort. During 2009-2010 he served as a technical consultant to the Obama Administration and worked with both the Administration and Congress to help craft the Patient Protection and Affordable Care Act. In 2011 he was named “One of the Top 25 Most Innovative and Practical Thinkers of Our Time” by Slate Magazine. In both 2006 and 2012 he was rated as one of the top 100 most powerful people in health care in the United States by Modern Healthcare Magazine. Dr. Gruber is the Chair of the Industry Advisory Board for Flare Capital Partners, and is on the board of the Health Care Cost Institute.

CARLEEN HAWN Co-Founder and CEO, HealthspottrCarleen Hawn is Co-Founder and CEO of Healthspottr. Previously, she spent 15 years as a business journalist, notably as Associate Editor with Forbes and later as Senior Writer and West Coast Bureau Chief for Fast Company magazine. With Forbes, Carleen conceived of and created the well-known Midas List, an index of leading venture capital dealmakers, currently in its

sixteenth year of publication. Carleen holds a BA in political science from Barnard College, an MS from Columbia Journalism School, and she was a Knight-Bagehot Fellow at Columbia Business School. She has served on the Editorial Advisory Board of TEDMED and is currently a Board Director of CureSearch, a national non-profit foundation that accelerates the search for cures for children’s cancers. Carleen currently serves as an Advisory Board member to Minneapolis-based Adrenaline Health, and to Thelander Consulting, Silicon Valley’s leading executive compensation data firm.

15

16

LEE J HELMAN, M.D. Professor, Pediatrics and Medicine, USC Director, Cancer and Blood Diseases Research Program Head, Basic and Translational Research Children’s Center for Cancer and Blood DiseaseLee J. Helman received his M.D. from the University of Maryland School of Medicine magna cum laude and was elected to Alpha Omega Alpha. He completed his internship and residency in internal medicine at Barnes Hospital, Washington University. Dr. Helman completed training in medical

oncology at the National Cancer Institute. He did his post-doctoral training in the Molecular Genetics Section, Pediatric Branch, NCI, and became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and as Scientific Director for Clinical Research in the Center for Cancer Research, NCI, from 2007 to 2016. He joined Children’s Hospital Los Angeles and the University of Southern California in 2017 as professor of Pediatrics and Medicine at the Keck School of Medicine and Director of Basic and Translational Research within the Children’s Center for Cancer and Blood Diseases at CHLA and is a member of the USC Norris Comprehensive Cancer Center. Dr. Helman’s laboratory work focuses on the biology and treatment of rhabdomyosarcoma, Ewing’s sarcoma, osteosarcoma, and pediatric GIST tumors. Major areas of research include the pathophysiologic consequences of IGF signaling, identification of the molecular/biochemical determinants of the biology of sarcomas, and the application of functional genomics to identify new treatment targets.

RAMY IBRAHIM, M.D. Vice President and Head of Research & Development, Parker Institute for Cancer Immunotherapy Ramy Ibrahim, M.D., is a recognized leader of clinical development in immunotherapy. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. Dr. Ibrahim currently serves as vice president of clinical development at the Parker Institute for Cancer Immunotherapy.

As part of his role, he has built a clinical trial management capabilities within the Institute that enabled the conduct of multi-center clinical trials across the Parker centers. His team is focused on supporting novel combinations that are science driven and innovative.

Throughout his career, Dr. Ibrahim has been involved with global cancer immunotherapy societies such as the Society of Immunotherapy for Cancer (SITC), Friends of Cancer research, the Cancer Research Institute and Cancer Support Community (CSC). He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.

17

YUKO ISHII, PH.D.Associate Director | Bristol-Myers Squibb Yuko Ishii graduated with a Ph.D. degree in psychology from University of Leeds, UK, fully funded by GlaxoSmithKline. Later trained as a post-doc in multi-countries including USA, Sweden and France. Prior to BMS, Yuko Ishii served as a translational medicine lead in oncology programs including first-in-class IDH inhibitor in Agios Pharmaceuticals and multiple oncology drugs

in Takeda Pharmaceuticals. Currently, a biomarker lead for the late stage assets at Bristol-Myers Squibb, namely Nivolumab RCC and IDO programs and supporting pediatric effort.

KATHERINE A. JANEWAY, M.D. Pediatric Hematologist-Oncologist, Dana-Farber Cancer Institute Katherine A. Janeway received her medical degree from Harvard Medical School in 2000. She subsequently completed her residency in Pediatrics at Children’s Hospital, Boston. She was a Chief Resident at Childrens Hospital, Boston, and then completed her fellowship in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute / Children’s Hospital, Boston. 

In 2007, Dr. Janeway joined the staff of Dana-Farber and Children’s Hospital, Boston, where she is a pediatric hematologist-oncologist and investigator with a research focus of pediatric sarcomas.

SU YOUNG KIM, M.D., PH.D. Medical Director, AbbVie Su Young Kim, M.D., Ph.D. graduated from the University of Chicago Pritzker School of Medicine and obtained his Ph.D. at the University of Illinois at Chicago, focusing on tumor suppressor genes. He received this fellowship training in pediatric hematology-oncology at the joint program at the Johns Hopkins University and the National Institutes of Health. He remained at the

NIH as an assistant clinical investigator, working on osteosarcoma translational research and helping to develop the NIH pediatric and wildtype gastrointestinal stromal tumor clinic.

Su Young joined AbbVie in 2014 and assumed the role of medical director of several CLL clinical studies, contributing to approvals worldwide. He leads the venetoclax pediatric program and established the global strategy for its use in multiple pediatric indications. He also expanded the use of venetoclax to a new indication, by combining it with navitoclax in children and adults with acute lymphoblastic leukemia.

18

KAY KOEHLER Chief Executive Officer, CureSearch for Children’s Cancer With over 15 years’ experience in the non-profit sector, Kay Koehler joined CureSearch in May 2017 as Chief Development Officer. In that role, she successfully built philanthropic, fundraising and communication strategies for the organization, leading their implementation across all sectors. In February 2018, the Board of Directors appointed her CEO. Her focus is on driving

collaborative and innovative solutions to the therapeutic challenges of pediatric cancer.

Prior to CureSearch, Kay held executive leadership positions at the American Heart Association and, most recently, the Leukemia & Lymphoma Society (LLS), where she was heavily engaged in the Beat AML Master Trial. As a key contributor to the development of the Beat AML campaign, Kay worked with leading researchers Drs. Druker, Byrd and Levine to secure its first gift - the largest in the Society’s 60-year history. She later built and directed the Planned Gifts effort, rolling out the organization’s inaugural program to the field, and securing $33M in its first two years.

Kay spent the first half of her career in for-profit organizations, where she led global strategic alliance efforts and international sales teams in small to mid-tier B2B software companies, most recently Citrix Systems, Inc.

Kay holds a B.A. from Augustana College in Rock Island, IL, where she graduated magna cum laude with a triple major and was inducted into the Phi Beta Kappa Honor Society.

ERIN KOZAKI Vice President, Philanthropy, CureSearch for Children’s CancerErin Kozaki joined CureSearch for Children’s Cancer in July 2017 as a Major Gifts Officer and was promoted to Vice President, Philanthropy in March 2018. Erin develops and executes a comprehensive development plan focused on securing major gifts in support of CureSearch initiatives and programs. She works with the Board of Directors and Executive team to

engage donors to achieve high levels of philanthropic support.

Prior to joining CureSearch, Erin worked with The Leukemia & Lymphoma Society as a Regional Major Gift Officer and Donor Development Director where she served as a major gift fundraiser for the California Southland, San Diego/Hawaii, Arizona, and Rocky Mountain (Colorado/Wyoming) Chapters of the organization. She engaged with high-level donors and provided leadership to staff across these chapter areas. Erin has held the Executive Director and Development Director positions at Jodi House, Inc. in Santa Barbara, California as well as Development Director at CASA of Santa Barbara County.

Erin has a bachelor’s degree in Criminal Justice from the University of Nevada at Las Vegas, and she currently resides in Santa Barbara, CA.

NEIL KUMAR, PH.D. CEO and Founder, BridgeBio Pharma, LLCNeil Kumar, Ph.D., is the CEO and Founder of BridgeBio Pharma, LLC, a company focused on the development of novel therapies for rare genetic disorders. Prior to that, he was a principal at Third Rock Ventures where he supported and managed various portfolio companies in addition to focusing on new company formation and due diligence. He also held the role of Vice

President, Business Development and Operations for MyoKardia. Prior to joining Third Rock, Dr. Kumar was an associate principal at McKinsey & Company, where he developed strategies for pharmaceutical and medical device companies and helped lead McKinsey’s personalized medicine efforts. Before joining McKinsey, Dr. Kumar was involved in the formation of a gene chip startup and was a technical consultant for AstraZeneca’s pathway signaling group. Dr. Kumar is the author of several peer-reviewed papers in the fields of oncology and systems biology.

Dr. Kumar holds B.S. and M.S. degrees in chemical engineering from Stanford University.He received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.

19

ANDREW L. KUNG, MD, PH.D.Chair, Department of Pediatrics, Lila Acheson Wallace Chair for Pediatric ResearchDr. Kung received his medical degree and Ph.D. in cancer biology from Stanford University School of Medicine. He completed his residency training at Boston Children’s Hospital followed by fellowship in Pediatric Hematology-Oncology at Boston Children’s Hospital/Dana-Farber Cancer

Institute. After faculty positions at Harvard Medical School and Columbia University Medical Center, Dr. Kung joined MSK in July 2016, succeeding Dr. Richard O’Reilly as Chair of the Department of Pediatrics. Dr. Kung specializes in caring for patients using cancer genomics, precision medicine, and stem cell transplantation. In addition to patient care, Dr. Kung directs research focused on identifying the causes of pediatric cancers and developing new treatments to benefit children and teens with cancer. Studies from his laboratory have been advanced to clinical trials for brain tumors, leukemia and sarcoma. As Chair, Dr. Kung oversees the clinical, research, and educational missions of one of the largest pediatric oncology programs in the world.

20

STEPHEN LESSNICK, M.D., PH.D.Director, Center for Childhood Cancer and Blood DiseasesThe Research Institute at Nationwide Children’s Hospital Columbus, OHDr. Lessnick earned his bachelor’s degree from Brandeis University, followed by M.D. and Ph.D. degrees from the University of California, Los Angeles (UCLA), as part of the Medical Scientist Training Program (MSTP). He did

his Ph.D thesis with Christopher Denny, M.D., where he studied the function of the Ewing sarcoma EWS/FLI oncoprotein. He then conducted his internship and residency at Children’s Hospital in Boston, Massachusetts, followed by a fellowship in pediatric hematology/oncology at Children’s Hospital and Dana-Farber Cancer Institute in Boston. He completed postdoctoral research in the Pediatric Oncology Department at the Dana-Farber Cancer Institute with Todd Golub, M.D., where he studied the transcriptional consequences of EWS/FLI.

Dr. Lessnick joined University of Utah faculty in January 2004 and rose through the ranks to become a Tenured Professor of Pediatrics in the Division of Pediatric Hematology/Oncology, a Jon and Karen Huntsman Presidential Professor in Cancer Research, and the Director of the Center for Children’s Cancer Research at Huntsman Cancer Institute. In July 2015, Dr. Lessnick joined the faculty at The Research Institute at Nationwide Children’s Hospital as the director of the Center for Childhood Cancer and Blood Diseases and The Ohio State University as a professor of Pediatrics in the Division of Pediatric Hematology/Oncology.

LORETTA LI, M.D. Pediatric Oncology Researcher, Dana Farber Cancer Institute CureSearch Young Investigator Loretta is a pediatric oncologist at Boston Children’s Hospital and the Dana-Farber Cancer Institute. As a junior faculty member in the laboratory of David Weinstock, M.D, she has been leading efforts to study mechanisms of response and resistance to type II Janus kinase 2 (JAK2) inhibitors in

B-cell acute lymphoblastic leukemia, the most common form of cancer in children. She is nowcollaborating with Dr. Nathanael Gray’s lab at the Dana-Farber Cancer Institute to validate thepreclinical activity of novel type II JAK2 inhibitors and explore targeted degradation of theJAK2 protein as an alternative therapeutic strategy for JAK2-dependent leukemia’s. In thefuture, she would like to use her dual training in clinical medicine and laboratory research tomore expeditiously bring promising novel therapies to clinical trials for patients.

21

ANDREW W. LO, PH.D. Professor of Finance, Massachusetts Institute of Technology (MIT) and Director, MIT Laboratory for Financial Engineering Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management and director of the MIT Laboratory for Financial Engineering. He received his Ph.D. in economics from Harvard University in 1984. Before joining MIT’s finance faculty in 1988, he taught at the University

of Pennsylvania’s Wharton School as the W.P. Carey Assistant Professor of Finance from 1984 to 1987, and as the W.P. Carey Associate Professor of Finance from 1987 to 1988.

He has published numerous articles in finance and economics journals, and has authored several books including Adaptive Markets: Financial Evolution at the Speed of Thought, The Econometrics of Financial Markets, A Non-Random Walk Down Wall Street, Hedge Funds: An Analytic Perspective, and The Evolution of Technical Analysis. He is currently co-editor of the Annual Review of Financial Economics and an associate editor of the Financial Analysts Journal, the Journal of Portfolio Management, and the Journal of Computational Finance.

His awards include the Alfred P. Sloan Foundation Fellowship, the Paul A. Samuelson Award, the American Association for Individual Investors Award, the Graham and Dodd Award, the 2001 IAFE-SunGard Financial Engineer of the Year award, a Guggenheim Fellowship, the CFA Institute’s James R. Vertin Award, the 2010 Harry M. Markowitz Award, and awards for teaching excellence from both Wharton and MIT.

MIKE MILLER, ESQ. Senior Partner, Miller Tack & Madson Board of Director, CureSearch for Children’s Cancer Mike is Board Certified by the Florida Bar in Labor and Employment Law and has been practicing exclusively in the area of labor and employment law for his entire 45 year legal career. Mike has written or assisted in writing all of Florida’s employee leasing/PEO legislation ranging from

PEO licensing, workers’ compensation exclusivity of remedy, tort reform, to all other PEO legislative endeavors. Since the inception of the Florida Association of Professional Employer Organizations in 1986 he has served as the Association’s General Counsel. Also, since 1984 he has served as labor counsel to the Florida Health Care Association. Mike is rated “AV” by MartindaleHubbell, the national lawyers rating service, which is the highest rating a lawyer can receive. He has also been listed in the Florida Super Lawyers publication since 2006 in Employment & Labor Law. Mike also proudly and passionately serves on the Board of Directors of CureSearch for Children’s Cancer – a nationwide organization dedicated to the funding and discovery of effective treatments for various forms of childhood cancer.

22

DEBORAH MOROSINI, M.D., MSWVice President, Clinical Affairs & Patient Engagement, LOXO Oncology, Inc. Deborah Morosini, M.D., MSW joined LOXO Oncology in 2016 as vice president of clinical affairs & patient engagement, bringing expertise in oncology drug development, clinical genomics and insightful philanthropic activism. Loxo Oncology, Inc. is a biopharmaceutical company innovating the

development of highly selective medicines for patients with genetically defined cancers. As an early team member & VP at Foundation Medicine (FMI), she developed a niche specialty in the genomics of adolescent and young adult (AYA) cancer. Prior to joining FMI, she founded and led the molecular pathology group at AstraZeneca US, where she helped develop and implement biomarker strategies for biomarker driven trials. She currently serves on the Board of Directors for the National Comprehensive Cancer Network (NCCN) Foundation, the Bonnie J. Addario Lung Cancer Foundation, the National Patient Advocate Foundation (NPAF)scientific advisory board, Target Cancer, the NHGRI council, Cancer Support Community: NewJersey, and the development subcommittee for the AYA cancer foundation, Critical Mass.

DOUG ONSI, J.D. Managing Director, HealthCare Ventures, LLC Douglas E. Onsi, J.D. is a Managing Director at HealthCare Ventures and the chief financial officer of Leap Therapeutics, Inc. He was previously at Genzyme Corporation, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology and as Vice President, Business Development. Prior to joining Genzyme, Doug

was chief financial officer of Tolerx, Inc., a venture capital funded immunology company. Before joining Tolerx, he was in business development at LeukoSite, Inc., a publicly-traded oncology company that was sold to Millennium Pharmaceuticals. He began his career as an attorney at Bingham Dana LLP, representing biotech companies such as LeukoSite and Cubist Pharmaceuticals. He received a Juris Doctor degree from the University of Michigan Law School and an undergraduate degree in biology from Cornell University.

RICHARD J. O’REILLY, M.D.Chairman, Department of PediatricsChief, Bone Marrow Transplantation Service Memorial Sloan Kettering Cancer CenterRichard J. O’Reilly, M.D. is Chairman of the Department of Pediatrics and Director of the Bone Marrow Transplantation Program at Memorial Sloan-Kettering Cancer Center. Dr. Richard J. O’Reilly has pioneered the development of curative marrow transplantation approaches for patients who lack HLA matched siblings. He and his colleagues introduced the use of

matched unrelated donors and T-cell depleted transplants from HLA half matched donors in order to provide a normal blood system without GvHD to patients afflicted with lethal immune deficiencies and leukemia. His laboratory is currently exploring the potential of adoptive cell therapies employing immune cells grown in vitro to treat or prevent infections and recurrence of leukemia following transplantation.

Dr. O’Reilly received his M.D. from the University of Rochester School of Medicine in Rochester, New York in 1968. He completed his residency in pediatrics at Children’s Hospital Medical Center in Boston and specialty training in infectious disease at the Children’s Hospital and Beth Israel Hospital in Boston. He initiated the marrow transplant program at Memorial Sloan-Kettering Cancer Center in 1974, and was appointed Director and Chief of the Transplant Program in Pediatrics in 1976. From 1976 until 2004, he was also Chief of the Allogeneic Marrow Transplantation Service in the Department of Medicine. He has also served as Chairman of the Department of Pediatrics since 1986. Dr. O’Reilly is the incumbent of the Claire L. Tow Chair in Pediatric Oncology Research.

He has received numerous honors since 1968, including the Lila Acheson Wallace Chair of Pediatric Research, the Louise and Allston Boyer-Young Investigator Award – Clinical Research, The Vincent Astor Chair of Clinical Research, Distinguished Alumnus Award – MSKCC, the Herman Boerhaave Medal from the University of Leiden, the McGovern Award of the Houston

Academy of Medicine, the Lifetime Achievement Award from the American Society of Blood and Marrow Transplantation, the Pediatric Oncology Award from the American Society of Clinical Oncology, and the Bob Pinedo Cancer Care Prize of the Society for Translational Oncology.

Dr. O’Reilly is the author or co-author of over 360 articles on the topic of bone marrow transplantation and transplantation immunology.

23

24

ANDY DJ PEARSON, M.D. Retired Professor of Pediatric OncologyInstitute of Cancer Research and Royal Marsden Hospital, EnglandAndy DJ Pearson, M.D., is formerly a Cancer Research UK Professor of Pediatric Oncology, at the Institute of Cancer Research and the Royal Marsden Hospital NHS Trust. In May 2014 he retired due to ill health from The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. Prior

to 2005 he had been Professor of Paediatric Oncology, University of Newcastle upon Tyne and Dean of Postgraduate Studies, Faculty of Medical Sciences, University of Newcastle upon Tyne. Professor Pearson trained at Newcastle upon Tyne and was Lilly International/Medical Research Council Travelling Fellow at the University of Minnesota.

Professor Andy Pearson’s expertise is in the fields of drug development and neuroblastoma and has over 40 years’ experience in clinical pediatric oncology. Professor Pearson led the first pediatric phase I study in the UK. He has been involved in the pre-clinical and early clinical development of many anti-cancer agents in children. He was Chair of National Cancer Research Institute Children’s Cancer and Leukemia Clinical Studies Group Novel Agents Subgroup and a member of New Agents Committee of Cancer Research UK. He is a member of the Executive and Clinical Trial Committee of the Innovative Therapy for Children with Cancer Consortium (ITCC). He is a member of the Steering Committee of the multi-stakeholder CDDF – ITCC – International Society of Pediatric Oncology Europe (SIOPE) Pediatric Oncology Platform (ACCELERATE) to improve drug development for children and adolescents with cancer. He has been on the Organizing Committee of the ACCELERATE-European Medicine Agency (EMA) Pediatric Strategy Forums. He led a comprehensive pediatric drug development program, with one of the largest portfolios of early phase, first in child, biomarker rich studies in Europe at The Institute of Cancer Research and Royal Marsden focusing on neuroblastoma.

He was the first Chair of the United Kingdom Children Cancer Study Group (UKCCSG) Neuroblastoma Group, Chair of the European Neuroblastoma Group and was the founding chair of International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN). He remains on the Advisory Board of SIOPEN. He and Professor Sue Cohn of Chicago created and chair the International Neuroblastoma Risk Group Consortium (INRG). He was President of Advances in Neuroblastoma Research Association from 2012 – 2014 and was on the ANRA Advisory Board for Europe and Russia since 2006. He was Chairman of the UKCCSG from 2003 – 2006. Professor Pearson was the Chief Investigator of the clinical trial ENSG 5 which changed the standard practice for the therapy of high risk neuroblastoma in Europe. He was the Chief Investigator of the BEACON Trial; the first randomized European study for refractory/relapsed neuroblastoma. He has published over 350 scientific manuscripts.He was awarded a Life Time Achievement Award from Advances in Neuroblastoma Research in 2016.

25

GREGORY REAMAN, M.D.Associate Director for Pediatric Oncology, FDAGregory H. Reaman, MD joined the Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration as the Associate Director for Oncology Sciences of the Office of Hematology and Oncology Products (OHOP) in 2011. He is the Founding and Immediate Past Chair of the Children’s Oncology Group (COG) having served in this capacity from 2000 through 2010 and previously served as Vice Chair for Scientific Affairs and Associate Chair for New Agent Studies of the legacy

Children’s Cancer Group (CCG) where he directed the Phase 1 Consortium for 10 years.

Dr. Reaman is a Professor of Pediatrics at George Washington University School of Medicine and Health Sciences and a member of the Division of Hematology-Oncology at the Children’s National Medical Center in Washington, DC, which he directed for more than 17 years. He serves or has served on numerous Editorial Boards and is the author/co-author of more than 350 peer – reviewed manuscripts and 20 book chapters and the editor/associate editor of four textbooks. His research interests are in biology and treatment of childhood acute leukemia and new drug development for pediatric cancer.

ROSANNA RICAFORT, M.D. Clinical Program Lead for Hematology – Oncology Research Development, Bristol-Myers Squibb Rosanna Ricafort is a pediatric hematologist/oncologist and Executive Director for Hematology-Oncology Clinical Development at Bristol-Myers Squibb, responsible for the clinical development programs of immune-oncology assets across hematology and pediatrics. Her team drives individual asset strategies from design through execution of specific data

generation trials, including registrational, non-registrational, external collaborations and other business development activities. She leads the Pediatric Development Team and is a core member of the Hematology Development Team, focused on the vision and growth of Oncology asset development strategies, including consideration for scientific, regulatory and clinical activities. Rosanna started her industry career in 2013 and held increasing leadership positions in the U.S. Medical Affairs organizations at BMS and Celgene, delivering successful launches for four different immuno-oncology assets across disease indications in hematologic malignancies.

Rosanna established and directed the Pediatric Blood and Marrow Transplantation Program at Montefiore Medical Center, NY, where she held a faculty appointment for over 10 years. Rosanna led the clinical transplant program’s successful FACT accreditation, recognition as a COG Transplant Center and membership to the NM.D.P and PBMTC. In addition, she was the COG Site PI. Rosanna completed her fellowship training in Pediatric Hematology and Oncology at Memorial Sloan-Kettering Cancer Center in New York.

26

ANDREW RYSCAVAGE, M.A., M.B.A.Strategy Consultant, Monitor Deloitte Andrew is a strategy consultant with Monitor Deloitte. He works with commercial, federal, and non-profit clients to develop data driven and actionable strategic plans. Andrew also develops economic impact analyses and business growth strategies for R&D heavy markets. He has deep experience in alternative innovation strategies such as innovation centers, data-driven catalysis, the prize model, and associated prize design. He is

also a scientist with over 14 years’ experience doing cancer research and management at the National Cancer Institute. His scientific research focused on establishing molecular markers for lesions with a high-risk for becoming invasive cancer. He published 15 peer reviewed journal articles and 1 book chapter. Andrew is also the project manager for Deloitte’s Cancer XPRIZE efforts.

SARITA K. SASTRY, PH.D.National Director, Research and Programs, CureSearch for Children’s Cancer Sarita K. Sastry, Ph.D., National Director, Research and Programs, oversees CureSearch’s pediatric cancer research grant portfolio, the $10M Acceleration Initiative and the Young Investigator’s Program. Dr. Sastry also administers the CureSearch Scientific Advisory Council and Scientific Review Committee and serves as a liaison between academic pediatric cancer researchers and key stakeholders: donors, advocates, strategic

partners etc. She further oversees educational content, grants to support community hospitals, childhood cancer survivorship awareness and patient advocacy.

Before joining CureSearch in 2015, Dr. Sastry received a Ph.D. in Biochemistry from the University of Illinois and completed post-doctoral research training in cell biology at the University of North Carolina at Chapel Hill. Dr. Sastry spent several years as a faculty member at the University of Texas Medical Branch in Galveston, TX, where she was engaged in NCI-funded cancer research, teaching, publishing research and review articles and reviewing research grants. She brings her subject matter expertise to CureSearch to help find new cures for pediatric cancers.

KENNETH SCHANER, J.D.Owner, Schaner & Lubitz, PLLCKenneth Schaner, J.D., is Owner of Schaner & Lubitz, PLLC. In his more than 40 years of private practice, Ken has represented many for profit and non-profit entities in the corporate and tax aspects of a wide variety of agreements, transactions, financings, licenses, mergers and acquisitions.

Ken began his career at the Internal Revenue Service’s (IRS) legislative and regulations division. During his time with the IRS, Ken worked on the 1969 Tax Reform Act and was one of the principal drafters of the new private foundation provisions. In 1982, Ken co-founded Swidler Berlin, LLP. While a partner in that firm, he also served as Managing Member and Chair of the corporate group. After Swidler Berlin’s merger with Bingham McCutchen, LLP in 2006, Ken remained a partner until 2008, when he formed Schaner & Lubitz to focus on representing tax-exempt organizations. Since 1983, Ken has served as General Counsel to the Cystic Fibrosis Foundation (CFF). In that capacity, Ken represented CFF in its first venture philanthropy transaction with Aurora Biosciences Corporation (now Vertex), and subsequently represented CFF’s affiliate, CFFT, in the historic monetization of the Vertex royalty interest in 2014. Ken has represented numerous clients in venture philanthropy transactions and related legal matters. Ken also serves as general and outside counsel to many non-profits.

ELIZABETH SHAUGHNESSYSenior Associate, Tapestry Networks Elizabeth (Liz) Shaughnessy is a senior associate in Tapestry Networks’ healthcare practice and works to bring together diverse stakeholders to address urgent, big-picture challenges in business and healthcare. She supports Tapestry’s work in diagnostic innovation and genomics, diagnostic quality assurance, and innovative financing and payment reform for

transformative therapies.

Prior to Tapestry, Liz spent the last eight years working at the intersection of international trade, business development, and global health, first as a program manager at the Corporate Council on Africa and most recently as a senior manager at advisory firm Development Finance International, Inc. There, she specialized in working with life sciences companies on market entry strategy and expansion in frontier markets.

Liz received her M.A. in global, international, and comparative history from Georgetown University. She received her B.A. from College of the Holy Cross in english and history.

STUART SIEGEL, M.D. Board Chair, CureSearch for Children’s CancerStuart Siegel, M.D. is Chair of the CureSearch Board of Directors. Stuart was the Founding Director of the Children’s Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles and Professor of Pediatrics and Medicine at the Keck School of Medicine at the University of Southern California until his retirement at the end of 2015. In addition to his leadership

in pediatric oncology, Stuart has been a local, national and international leader in the development of academic and clinical care programs for adolescents and young adults with cancer. 

27

DONALD SMALL, M.D, PH.D.Professor of Oncology, Pediatrics, Cellular and Molecular Medicine, and Human Genetics, John Hopkins University School of Medicine Don Small, M.D., Ph.D received his undergraduate, M.D., and Ph.D degrees from the Johns Hopkins University (1979, 1985). He trained in pediatrics and pediatric hematology/oncology at Hopkins. During his pediatric Hematology/Oncology fellowship, he studied the role of a number of proteins in DNA replication. He joined the Hopkins faculty in 1990, and was named the Kyle Haydock Professor of Oncology in 2003, with joint

appointments in Pediatrics, Cellular and Molecular Medicine, and Human Genetics. He has served as Director of Pediatric Oncology at Johns Hopkins since 2006.

His laboratory was the first to clone the human FLT3 gene, which is the most frequently mutated gene in acute myeloid leukemia (AML). He led the team that investigated the role of FLT3 in leukemia and was the first to discover drugs capable of inhibiting the tyrosine kinase activity of FLT3. This research revealed that this class of drugs could preferentially kill leukemic cell lines and primary AML samples expressing mutant FLT3–one of the first successful molecularly targeted cancer therapies. His lab also developed a high-throughput cell-based in vitro assay that facilitated screening of a large library of kinase inhibitors and identification of several with great potency and selectivity against FLT3. His group led the first clinical trials investigating the use of a FLT3 inhibitor in adult relapsed and refractory FLT3-mutant AML, and determined how best to combine these drugs with chemotherapy. The team also helped design the first pediatric trials of FLT3 inhibitors for use in treating pediatric AML and infant ALL.

His lab continues to investigate the process of leukemic transformation, the role of FLT3 in leukemia stem cells utilizing mouse models, and signaling changes in leukemic stem cells.

ALLISON SOLE Research Director, Alan B. Slifka Foundation Allison brings more than 15 years of experience in the philanthropic sector to her role at the Alan B. Slifka Foundation as its director of biomedical programs with a focus on sarcoma. Prior to completing a yearlong project at Google, Allison served as inaugural deputy director of 21/64, a consulting division of the Andrea and Charles Bronfman Philanthropies specializing in fostering multigenerational family philanthropy. She worked with

family foundations and related entities and developed original resources to help facilitate philanthropic conversations about values and legacy. Her interest and commitment to the next generation began when she was a psychoeducational counselor for youth. She applied this interest to the Arnold P. Gold Foundation for Humanism in Medicine, a philanthropy dedicated to sustaining the commitment of healthcare professionals, including doctors-in-training, to provide compassionate, collaborative and scientifically excellent patient care, and where she was a Programs Director. She is gratified by the opportunity to work among a community of dedicated clinicians and researchers who are seeking curative therapies for bone and soft-tissue sarcomas.

28

29

MARK SORRENTINO, M.D., M.S.Vice President, Center for Pediatric Clinical Development, PRA Health Sciences Mark Sorrentino, M.D., M.S., has 20 years of experience in the pharmaceutical and biotech industries. He is currently the Vice President, Center for Pediatric Clinical Development at PRA Health Sciences. Prior to joining PRA, Dr. Sorrentino spent 5 years as the global chair and founder of the pediatric

practice area overseeing all aspects of strategy and clinical development in pediatrics. He was also the global therapeutic head of critical care.

Dr. Sorrentino has served as a consultant to biotechnology firms and has overseen implementation of medical information systems. Dr. Sorrentino received his MD as well an MS in Clinical Nutrition from the Chicago Medical School. He completed both a residency in Pediatrics and fellowship in Pediatric Critical Care at Children’s National Medical Center in Washington DC and currently holds an appointment as an Assistant Clinical Professor at the George Washington University School of Medicine. Dr. Sorrentino was an attending physician in the CNMC pediatric intensive care unit for 8 years and participated in numerous Industry sponsored critical care trials.

CESARE SPANDONI, PH.D, M.B.A. Chief Operating Officer and Co-Founder, Oncokids Biosciences Inc.Cesare is Chief Operating Officer and Co-Founder of Oncokids Biosciences Inc, a biotech company exclusively focused on pediatric oncology drug development. Cesare has more than 20 years of experience in the drug development field, in both scientific and commercial roles. He started his

career as a research scientist in a pharmaceutical company (Eisai London) and in academia (Institute of Enzymology, Budapest). He has held senior positions at AMRI, Aptuit Laurus, ThalesNano and is currently a consultant for Auxiliis, a Dutch clinical CRO.

Following the death of his daughter Laura to cancer, Cesare set up the aPODD Foundation, a London-based charity focused on accelerating pediatric oncology drug development. As aPODD’s chairman he is actively involved in drug development and drug repurposing projects by partnering with several childhood cancer charities.

Cesare holds an MSc in Applied Molecular Biology and a Ph.D in Neuroscience from the University of London, as well as an MBA from the Central European University, Budapest.

NETTIE SPARKMANFund Director, Love Your MelonNettie Sparkman is the Fund Director at Love Your Melon, an apparel brand that aims to make a meaningful impact in the lives of children battling cancer. Love Your Melon products are made in the USA and 50% of the company’s profit is given every year to nonprofit partners in the fight

against pediatric cancer.

Nettie comes from a family of entrepreneurs and finds fulfillment in giving back, creating a better world for children going through cancer treatment and working to achieve innovative solutions and cures for pediatric cancer. Nettie attended Iowa State University where she studied genetics before working at Love Your Melon.

30

LARA SULLIVAN, M.D., M.B.A. President & Founder, SpringWorks Therapeutics Lara Sullivan brings to SpringWorks Therapeutics more than two decades of experience and senior leadership in biopharmaceuticals, healthcare and life sciences, most recently at Pfizer. While at Pfizer she helmed strategy and portfolio operations for the company’s early stage pipeline and led the work, inside Pfizer and with outside patient groups and partners, to

create SpringWorks Therapeutics. Lara joined Pfizer from McKinsey & Company, where she was an associate partner in the pharmaceutical and medical products practice advising biopharmaceutical clients on a variety of strategic and operational issues, with a particular emphasis on R&D productivity. Additionally, Lara was a principal at Paul Capital Partners leading due diligence for investments in the healthcare fund, and earlier in her career worked in healthcare equity research and municipal finance at CS First Boston. Lara holds an M.D. from the University of Pennsylvania School of Medicine, an MBA from The Wharton School at the University of Pennsylvania, and a B.A. in comparative literature from Cornell University.

LISA W. TICHENOR President & Trustee, Quad WLisa W. Tichenor is a graduate of the University of Texas, where she earned a BBA in finance. In 2003, her sixteen-year-old son, Willie, was diagnosed with osteosarcoma and endured three years of intensive chemotherapy and surgery until his death in 2006. She, her husband, Mac, and son, Taylor, formed the What Would Willie Want Foundation (QuadW) and asked eight of Willie’s

best friends to be directors. QuadW addresses Willie’s desire to improve the world around him, including finding new treatment options for osteosarcoma patients. Lisa is on the Board of Directors of Africa University in Zimbabwe, and runs a community garden.

MAC TICHENOR, M.S., M.B.A. Executive Director, Quad W Mac Tichenor lost his 19-year old son, Willie, to osteosarcoma in 2006. Mr. Tichenor is Executive Director of the WWWW Foundation, which the Tichenors established in 2006 to support innovate sarcoma research, among other things. Last year, they launched the Osteosarcoma Institute to bring a focused effort to improving outcomes in that disease.

LOREN D. WALENSKY, M.D., PH.D. Associate Professor, Department of PediatricsAttending Physician in Pediatric OncologyPrincipal Investigator, Linde Program in Cancer Chemical BiologyDirector, Harvard/MIT M.D.-Ph.D ProgramDana-Farber Cancer InstituteLoren D. Walensky, M.D., Ph.D, is a Principal Investigator and Attending Physician in the Department of Pediatric Oncology and the Linde Program

in Cancer Chemical Biology at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Associate Professor of Pediatrics at Harvard Medical School, and Director of the Harvard/MIT M.D.-Ph.D Program.

Dr. Walensky’s research focuses on the chemical biology of deregulated apoptotic and transcriptional pathways in cancer and other pediatric diseases. The goal of his laboratory is to develop an arsenal of new compounds – a “chemical toolbox” – to investigate and block pathologic protein interactions. Dr. Walensky has broken new ground in our understanding of BCL-2 family protein interactions, which govern the critical balance between cellular life and death. His team has generated highly specific and stable “stapled peptides” that preserve the structure of biologically-active alpha-helices, maximizing their potential as novel tools to elucidate biological pathways and as prototype therapies for cancer, infectious diseases, and diabetes. His research contributed to the founding of Aileron Therapeutics, a Cambridge, Massachusetts biotechnology company, which has advanced to clinical trials a first-in-class stapled peptide drug to reactivate p53 in cancer, developed based on Dr. Walensky’s work.Dr. Walensky is the recipient of numerous awards including a Stand Up to Cancer Innovative Research Grant, an NIH Director’s Transformative RO1 Award, a Burroughs Wellcome Career Award in the Biomedical Sciences, a Leukemia and Lymphoma Society Scholar Award, a Harvard Medical School Young Mentor Award, and most recently, the Dana-Farber Cancer Institute’s Morse Award for Research Excellence, the Samuel Rosenthal Prize for Excellence in Academic Pediatrics, the E. Mead Johnson Award for Pediatric Research, and an NCI Outstanding Investigator R35 Award. He is a member of the American Society for Clinical Investigation, the Society for Pediatric Research and the American Pediatric Society.

IAN WALKER, PH.D, M.B.A.Director of Clinical, Population and Early Detection Research Cancer Research UK (CRUK)Ian has over 14 years of combined experience dedicated to advancements in cancer prevention, diagnosis, and treatment. First appointed as a CRUK Director in 2013, Ian has made significant contribution to the overall vision and efforts of the world’s largest medical research charity.

Ian holds various non-executive board level positions outside CRUK and has an exceptional record of building cross-sector partnerships to deliver consortia-based programmes.

Ian holds a Biochemistry B.Sc with honours and a Ph.D. from the University of Leeds. He also holds an M.B.A. with distinction from Warwick Business School.

31

KATHY WANNER Chair, Catapult Advisory CouncilKathy spent 22 years at Adams Street Partners, a global private equity firm with $30 billion in assets under management. After spending the first five years at Brinson Partners, ASP’s predecessor firm, in various roles, she joined the Private Equity group in 1998. Kathy was a founding team member for Adams Street which was established in 2001. While at Adams Street

Partners, Kathy managed the US Primary team and served on the Global Primary Investment Committee, which was responsible for implementing strategy and approving all primary fund investments. Since 1998, she served on many advisory boards and completed many primary investments across several sectors, ranging from healthcare to special situations. Prior to ASP, she was at Morgan Stanley in NYC. She holds a BS from Binghamton University and an MBA from Kellogg SOM at Northwestern University.

BRENDA J. WEIGEL, M.D. Chair, Developmental Therapeutics, Children’s Oncology Group Brenda Weigel, MD, is the Director of the Division of Pediatric Hematology/Oncology and is a Professor cross-appointed at the University of Minnesota’s Masonic Cancer Center and the Department of Pediatrics, and the recipient of the Lehman/Children’s Cancer Research Fund Endowed Chair in Pediatric Cancer. She is also the Co-Director of the Sarcoma Program for the Masonic

Cancer Center, and an Associate Director of the Cancer Experimental Therapeutics Initiative for the Masonic Cancer Center. Dr. Weigel is the medical director of the Masonic Cancer Center Clinical Trials Office. 

Dr. Weigel’s major interests have been advancing new therapies, particularly therapies that harness the immune system’s role in fighting cancer. Her research interests are centered in her extensive involvement with the Children’s Oncology Group (COG). She is the Chair of Developmental Therapeutics Committee, Co-chair for New High Risk Rhabdomyosarcoma Study, and the COG representative to the National Cancer Institute’s Investigational Drug Steering Committee.

32

33

KELLI WRIGHT National Director of Business Development, CureSearch for Children’s Cancer Kelli Wright, National Director of Business Development, leads an energetic team focused growing partnerships in the corporate and business world, and fostering collaboration with like-minded non-profits. Partners help end children’s cancer through corporate sponsorships, cause marketing/alliance

campaigns, workplace giving and our community and challenge events. As the sibling of a childhood cancer survivor, Kelli is extremely tied to the mission and knows first-hand the importance of raising dollars to fund life-saving children’s cancer research. 

ALLEN YANG, PH.D Vice President, Hematology/Oncology, Jazz Pharmaceuticals Allen joined Jazz Pharmaceuticals in March of 2016 and assumed the role as Therapeutic Area Head for Hematology/Oncology. He stepped in during the recent Celator transaction as a key member of the Integration Management Leadership team. His experience as a practicing oncologist has brought a unique perspective to the role and provided great value in collaborating

with our new Celator colleagues. Allen has been in the pharmaceutical industry for 7 years including roles at Amgen and Spectrum Pharmaceuticals as well as a Hematology/Oncology faculty position for 5 years at the University of Southern California. Allen holds a B.A. in Molecular Biology from UC Berkeley, and an M.D. and a Ph.D. in Biochemistry from University of Southern California. He completed his medical oncology fellowship at the M.D. Anderson Cancer Center.

curesearch.org

curesearch.org

The Catapult Summit brings together the most innovative minds in science, drug development, advocacy and health funding to focus on one very important goal:

finding less-toxic treatments and cures for children’s cancer.